caa a22 4500 465790097 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177258 doi (NATIONALLICENCE)springer-10.1007/BF00177258 Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix [Elektronische Daten] A Gynecologic Oncology Group study [William McGuire III, John Blessing, Kenneth Hatch, Michael Berman] Summary: Twenty patients with advanced measurable, squamous carcinoma of the cervix were treated with 25 courses of N-MF at doses ranging from 600-800 mg/m2, intravenously, daily for 5 days every 28 days. Nineteen patients are evaluable for toxicity and 17 for response. All patients had prior radiation and had received one prior chemotherapy regimen while only 10 patients had had prior surgery. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1, or 2. No responses were seen. Hematologic adverse effects were extremely rare as predicted by early clinical trials. One unusual toxicity was a syndrome consisting of pain, anorexia, lethargy, and declining performance status (pain/lethargy syndrome) that was reversible with discontinuation of the drug. This adverse effect was a reason for discontinuation of N-MF in two patients. As reported in previous studies with this drug, hepatic toxicity was also common, usually reversible, and also a cause for discontinuation of the drug. The lack of clinical activity and the unpleasant adverse effects in this population of patients with previously treated cervix cancer makes it unlikely that this drug will play any significant role in treatment. Kluwer Academic Publishers, 1990 N-MF nationallicence N-methylformamid nationallicence cervix neoplasms nationallicence McGuire III William Johns Hopkins Oncology Center, Baltimore, MD, USA aut Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut Hatch Kenneth Division of Gynecologic Oncology, The University of Alabama in Birmingham, Birmingham, AL, USA aut Berman Michael Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 195-197 0167-6997 8:2<195 1990 8 10637 https://doi.org/10.1007/BF00177258 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177258 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McGuire III William Johns Hopkins Oncology Center, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Blessing John Gynecologic Oncology Group, Cancer Research Scientist VI, Roswell Park Memorial Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Hatch Kenneth Division of Gynecologic Oncology, The University of Alabama in Birmingham, Birmingham, AL, USA aut NATIONALLICENCE 700 1- Berman Michael Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 195-197 0167-6997 8:2<195 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 465790011 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer